Susana Minguet

Dr. Susana Minguet

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 February 2018 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
APAlessandro Prestipino
Alessandro Prestipino
AEAlica J. Emhardt
Alica J. Emhardt
KAKonrad Aumann
Konrad Aumann
DODavid O’sullivan
David O’sullivan
SGSivahari P. Gorantla
Sivahari P. Gorantla
RZRobert Zeiser
Robert Zeiser
Recent evidence has revealed that oncogenic mutations may confer immune escape. A better understanding of how an oncogenic mutation affects immunosuppressive programmed death ligand 1 (PD-L1) expression may help in developing new therapeutic strategies. We show that oncogenic JAK2 (Janus kinase 2) activity caused STAT3 (signal transducer and activator of transcription 3) and STAT5 phosphorylation, which enhanced PD-L1 promoter activity and PD-L1 protein expression in JAK2V617F-mutant cells, whereas blockade of JAK2 reduced PD-L1 expression in myeloid JAK2V617F-mutant cells. PD-L1 expression was higher on primary cells isolated from patients with JAK2V617F–myeloproliferative neoplasms (MPNs) compared to healthy individuals and declined upon JAK2 inhibition. JAK2V617F mutational burden, pSTAT3, and PD-L1 expression were highest in primary MPN patient–derived monocytes, megakaryocytes, and platelets. PD-1 (programmed death receptor 1) inhibition prolonged survival in human MPN xenograft and primary murine MPN models. This effect was dependent on T cells. Mechanistically, PD-L1 surface expression in JAK2V617F-mutant cells affected metabolism and cell cycle progression of T cells. In summary, we report that in MPN, constitutive JAK2/STAT3/STAT5 activation, mainly in monocytes, megakaryocytes, and platelets, caused PD-L1–mediated immune escape by reducing T cell activation, metabolic activity, and cell cycle progression. The susceptibility of JAK2V617F-mutant MPN to PD-1 targeting paves the way for immunomodulatory approaches relying on PD-1 inhibition.

20 July 2020 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
FHFrederike A. Hartl
Frederike A. Hartl
EBEsmeralda Beck-Garcìa
Esmeralda Beck-Garcìa
NWNadine M Woessner
Nadine M Woessner
LFLea J. Flachsmann
Lea J. Flachsmann
RCRubí M.-H. Velasco Cárdenas
Rubí M.-H. Velasco Cárdenas
SMSusana Minguet
Susana Minguet

6 November 2023 in Nature Immunology
Verified
Journal Article
Open access
PDF file
RCRubí M.-H. Velasco Cárdenas
Rubí M.-H. Velasco Cárdenas
SBSimon M. Brandl
Simon M. Brandl
AMAna Valeria Meléndez
Ana Valeria Meléndez
ASAlexandra Emilia Schlaak
Alexandra Emilia Schlaak
ABAnnabelle Buschky
Annabelle Buschky
SMSusana Minguet
Susana Minguet
Current US Food and Drug Administration-approved chimeric antigen receptor (CAR) T cells harbor the T cell receptor (TCR)-derived ζ chain as an intracellular activation domain in addition to costimulatory domains. The functionality in a CAR format of the other chains of the TCR complex, namely CD3δ, CD3ε and CD3γ, instead of ζ, remains unknown. In the present study, we have systematically engineered new CD3 CARs, each containing only one of the CD3 intracellular domains. We found that CARs containing CD3δ, CD3ε or CD3γ cytoplasmic tails outperformed the conventional ζ CAR T cells in vivo. Transcriptomic and proteomic analysis revealed differences in activation potential, metabolism and stimulation-induced T cell dysfunctionality that mechanistically explain the enhanced anti-tumor performance. Furthermore, dimerization of the CARs improved their overall functionality. Using these CARs as minimalistic and synthetic surrogate TCRs, we have identified the phosphatase SHP-1 as a new interaction partner of CD3δ that binds the CD3δ–ITAM on phosphorylation of its C-terminal tyrosine. SHP-1 attenuates and restrains activation signals and might thus prevent exhaustion and dysfunction. These new insights into T cell activation could promote the rational redesign of synthetic antigen receptors to improve cancer immunotherapy.

21 October 2024 in Nature Reviews Immunology
Verified
Journal Article
Closed access
PDF file
SMSusana Minguet
Susana Minguet
MMMarcela V. Maus
Marcela V. Maus
WSWolfgang W.A. Schamel
Wolfgang W.A. Schamel

9 October 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
JBJulia Baaske
Julia Baaske
PGPatrick Gonschorek
Patrick Gonschorek
RERaphael Engesser
Raphael Engesser
ADAlazne Dominguez-Monedero
Alazne Dominguez-Monedero
KRKatrin Raute
Katrin Raute
MZMatias D. Zurbriggen
Matias D. Zurbriggen
Optogenetic switches are emerging molecular tools for studying cellular processes as they offer higher spatiotemporal and quantitative precision than classical, chemical-based switches. Light-controllable gene expression systems designed to upregulate protein expression levels meanwhile show performances superior to their chemical-based counterparts. However, systems to reduce protein levels with similar efficiency are lagging behind. Here, we present a novel two-component, blue light-responsive optogenetic OFF switch (‘Blue-OFF’), which enables a rapid and quantitative down-regulation of a protein upon illumination. Blue-OFF combines the first light responsive repressor KRAB-EL222 with the protein degradation module B-LID (blue light-inducible degradation domain) to simultaneously control gene expression and protein stability with a single wavelength. Blue-OFF thus outperforms current optogenetic systems for controlling protein levels. The system is described by a mathematical model which aids in the choice of experimental conditions such as light intensity and illumination regime to obtain the desired outcome. This approach represents an advancement of dual-controlled optogenetic systems in which multiple photosensory modules operate synergistically. As exemplified here for the control of apoptosis in mammalian cell culture, the approach opens up novel perspectives in fundamental research and applications such as tissue engineering.

14 August 2017 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
SMSusana Minguet
Susana Minguet
KKKathrin Kläsener
Kathrin Kläsener
ASAnna-Maria Schaffer
Anna-Maria Schaffer
GFGina J Fiala
Gina J Fiala
TOTeresa Osteso-Ibánez
Teresa Osteso-Ibánez
MPMiguel A. del Pozo
Miguel A. del Pozo